What does the management protocol for severe asthma include?

The management protocol for severe asthma often incorporates the use of bronchodilators to relieve acute symptoms and improve airway patency. Administering 500 mcg of Ipratropium bromide is a recognized component of managing severe asthma exacerbations. Ipratropium is an anticholinergic agent that works by relaxing the bronchial muscles, thus aiding in the dilation of the airways and providing additional bronchodilation alongside beta-agonists like Salbutamol.

The inclusion of Ipratropium bromide is particularly beneficial in cases of severe asthma, as it can be used in conjunction with other treatments and is generally well-tolerated. This can enhance therapeutic outcomes when managing severe episodes, especially in patients who may not respond adequately to beta-agonists alone.

Other options mentioned, such as specific dosages of nebulized Salbutamol or the use of only oral medications, do not align with the advanced protocols recommended for severe asthma, which typically require a combination of treatments, including nebulized or aerosolized medications. Additionally, high-dose corticosteroid treatment should be carefully monitored and tailored to the individual patient’s needs, rather than applied indiscriminately without oversight.

Therefore, including Ipratropium